Quarterly report pursuant to Section 13 or 15(d)

Acquisition of Aquarius Biotechnologies, Inc. (Details Textual)

v2.4.1.9
Acquisition of Aquarius Biotechnologies, Inc. (Details Textual) (Aquarius Biotechnologies, Inc. [Member], USD $)
 1 Months Ended
Jan. 29, 2015
Aquarius Biotechnologies, Inc. [Member]
  
Business Acquisition [Line Items]  
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares 4,608,020us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
/ us-gaap_BusinessAcquisitionAxis
= mtnb_AquariusBiotechnologiesIncMember
Business Acquisition, Share Price $ 0.46us-gaap_BusinessAcquisitionSharePrice
/ us-gaap_BusinessAcquisitionAxis
= mtnb_AquariusBiotechnologiesIncMember
Business Combination, Contingent Consideration, Upon Achieving Certain Future Clinical Milestone, Number of Shares Issuable 5,000,000mtnb_BusinessCombinationContingentConsiderationUponAchievingCertainFutureClinicalMilestoneNumberOfSharesIssuable
/ us-gaap_BusinessAcquisitionAxis
= mtnb_AquariusBiotechnologiesIncMember
Business Combination, Contingent Consideration, Upon Achieving Certain Future Regulatory Milestone, Number of Shares Issuable 3,000,000mtnb_BusinessCombinationContingentConsiderationUponAchievingCertainFutureRegulatoryMilestoneNumberOfSharesIssuable
/ us-gaap_BusinessAcquisitionAxis
= mtnb_AquariusBiotechnologiesIncMember
Milestone Consideration Description (i) 1,500,000 shares issuable upon the dosing of the first patient in a phase III trial sponsored by us for a product utilizing Aquarius’ proprietary cochleate delivery technology and (ii) 1,500,000 shares issuable upon FDA approval of the first NDA submitted by us for a product utilizing Aquarius’ proprietary cochleate delivery technology.